San Antonio Breast Cancer Symposium | Conference

Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer

January 14th 2020

Hope S. Rugo, MD, FASCO, discusses the updated findings of the SOPHIA trial in HER2-positive metastatic breast cancer.

Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer

January 14th 2020

Rashmi K. Murthy, MD, MBE, discusses the findings of the HER2CLIMB trial in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer

January 13th 2020

Martine J. Piccart, MD, PhD, discusses the 6-year follow-up of the APHINITY trial and its impact on the breast cancer field.

Real-World Abemaciclib Use in MBC Is Heterogeneous

January 3rd 2020

In the first 11 months following the FDA approval of the CDK4/6 inhibitor abemaciclib as a single agent and in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, it is being used heterogeneously, including in patients with characteristics indicative of worse prognosis.

Absolute Lymphocyte Count May Predict Eribulin Benefit in Breast Cancer

December 28th 2019

A high absolute lymphocyte count at baseline appears to be an independent predictor for longer overall survival in patients with metastatic breast cancer who are treated with eribulin mesylate.

Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC

December 16th 2019

Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.

Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk

December 16th 2019

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer

December 14th 2019

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Neoadjuvant Olaparib Combo Safe in Breast Cancer

December 14th 2019

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

December 14th 2019

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

December 14th 2019

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.

Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

December 14th 2019

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups

December 14th 2019

The invasive disease-free survival benefit with adjuvant T-DM1 versus trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy was observed regardless of the type of neoadjuvant chemotherapy used.

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

December 13th 2019

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect

December 13th 2019

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

December 13th 2019

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer

December 13th 2019

Subcutaneous trastuzumab with hyaluronidase-oysk in combination with intravenous pertuzumab and chemotherapy had a safety profile consistent with IV trastuzumab in first-line metastatic HER2-positive breast cancer treatment.

Neoadjuvant Durvalumab Regimen Shows Promise in TNBC

December 13th 2019

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

December 13th 2019

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.

Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer

December 13th 2019

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.